Glaxosmithkline Intellectual competitive analysis

Explore patent oppositions filed by Glaxosmithkline Intellectual against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 3, 2026
Patent NumberTitleApplicantOpposition Date
Anti-Pvrig Antibodies And Methods Of UseCOMPUGENMay 2, 2023
Pvrig Polypeptides And Methods Of TreatmentCOMPUGENJan 5, 2023
Purification Of Recombinantly Produced PolypeptidesMEDIMMUNEDec 3, 2021
Pharmaceutical Composition For Cancer TreatmentOSAKA UNIVERSITYNov 17, 2021
Methods For The Purification Of Proteins Using Caprylic AcidNOVO NORDISKOct 26, 2021
Buffers For Stabilization Of Lentiviral PreparationsNOVARTISAug 12, 2021
Therapeutic And Diagnostic Methods For CancerF HOFFMANN LA ROCHEJul 7, 2021
Improved Methods For Manufacturing Adoptive Cell TherapiesBLUEBIRD BIOJan 21, 2021
Therapeutic And Diagnostic Methods For CancerF HOFFMANN LA ROCHEDec 4, 2020
Medicinal Composition For Treating CancerOSAKA UNIVERSITYSep 30, 2020

Explore Glaxosmithkline Intellectual's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 3, 2026
Patent NumberPublication DateTitleTotal Oppositions
Oct 15, 2025Biopharmaceutical Compositions1
Apr 24, 2024Crystal Form Of Gsk1278863 And Preparation Method And Pharmaceutical Use Thereof1
Oct 11, 2023Fluticasone Furoate In The Treatment Of Copd3
Sep 21, 2022Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties And Methods Of Administering The Same3
May 4, 2022Topical Pharmaceutical Compositions1
Nov 11, 2020Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties And Methods Of Administering The Same4
Aug 19, 2020Novel Processes For The Production Of Oligonucleotides2
Jul 1, 2020Novel Pharmaceutical Composition2
Feb 26, 2020Buffer System For Protein Purification1
Dec 18, 2019Fluticasone Furoate In The Treatment Of Copd2

Latest PTAB cases involving Glaxosmithkline Intellectual

Discover the latest PTAB cases involving Glaxosmithkline Intellectual, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 7, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Glaxosmithkline Intellectual

IPR2020-01577Sep 4, 2020EPIZYMEGLAXOSMITHKLINETerminated-Settled
IPR2020-00327Dec 19, 2019EPIZYMEGLAXOSMITHKLINEFinal Written Decision
IPR2020-00328Dec 19, 2019EPIZYMEGLAXOSMITHKLINEFinal Written Decision
IPR2016-01315Jun 30, 2016GLAXOSMITHKLINEFIBROGENInstitution Denied
IPR2016-01315Jun 30, 2016GLAXOSMITHKLINEFIBROGEN, INC.Institution Denied
IPR2016-01318Jun 30, 2016GLAXOSMITHKLINEFIBROGENInstitution Denied
IPR2016-01318Jun 30, 2016GLAXOSMITHKLINEFIBROGEN, INC.Institution Denied
IPR2016-01319Jun 30, 2016GLAXOSMITHKLINEFIBROGENInstitution Denied
IPR2016-01319Jun 30, 2016GLAXOSMITHKLINEFIBROGEN, INC.Institution Denied
IPR2016-01320Jun 30, 2016GLAXOSMITHKLINEFIBROGENInstitution Denied

Peer Comparison New

IP litigation analysis comparing Glaxosmithkline Intellectual with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 3, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
GLAXOSMITHKLINE214363
GENERICS UK319 - - -
OSER5 - - -
TEVA PHARMACEUTICAL INDUSTRIES LTD2717 - -